Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 11:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ranolazine Clear all
Recruiting Phase 2 Interventional

A Study of Ranolazine in ALS

NCT06527222
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Swathy Chandrashekhar, MBBS
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Fairway, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 1 Interventional

Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine

NCT01546597
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Results available

Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients

NCT01648205
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Placebo, Ranolazine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 3 Interventional Results available

Ranolazine and Pulmonary Hypertension

NCT01174173
View directory record Official record
Conditions
Angina, Pulmonary Arterial Hypertension
Interventions
Ranolazine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 16, 2026, 11:03 PM EDT
Terminated Phase 2 Interventional Results available

Ranolazine Cardioprotection in PCI

NCT01767987
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Harvey Hahn
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Results available

11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension

NCT01917136
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
11C-acetate, [18F]Fluoro-2-deoxy-2-D-glucose, Cardiac MRI
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Sep 16, 2026, 11:03 PM EDT
Terminated Phase 4 Interventional Results available

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

NCT00832572
View directory record Official record
Conditions
Coronary Artery Disease, Pain, Peripheral Nervous System Diseases, Polyneuropathy
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Houma, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Sep 16, 2026, 11:03 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

NCT01675973
View directory record Official record
Conditions
Severe Renal Impairment
Interventions
RANEXA
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 4 Interventional Results available

Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction

NCT02133352
View directory record Official record
Conditions
Pulmonary Hypertension, Diastolic Left Ventricular Dysfunction
Interventions
Ranolazine
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Results available

Ranolazine Among Unrevascularized Chronic Stable Angina Patients

NCT02265796
View directory record Official record
Conditions
Angina
Interventions
Ranolazine, Sugar pill
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 3 Interventional Results available

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

NCT01472185
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
57
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Results available

Microvascular Coronary Disease In Women: Impact Of Ranolazine

NCT00570089
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 16, 2026, 11:03 PM EDT
Terminated Not applicable Interventional

Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction

NCT00574756
View directory record Official record
Conditions
Ranolazine, Diastolic Heart Failure, Tissue Doppler Ultrasound, Echocardiography
Interventions
ranolazine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Results available

Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)

NCT02147067
View directory record Official record
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Not applicable Interventional

The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot

NCT01480336
View directory record Official record
Conditions
Arrhythmia
Interventions
Amiodarone Plus Ranolazine, Amiodarone with Placebo
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Sep 16, 2026, 11:03 PM EDT
Not listed No phase listed Observational

Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy

NCT01804543
View directory record Official record
Conditions
Angina, Heart Disease
Interventions
Ranolazine
Drug
Lead sponsor
Westside Medical Associates of Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Not applicable Interventional Results available

Impact of Ranolazine on Coronary Microcirculatory Resistance

NCT01815957
View directory record Official record
Conditions
Coronary Microcirculation, Coronary Artery Disease, Myocardial Disease, Ischemia
Interventions
Rnalozine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 3 Interventional

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

NCT00998218
View directory record Official record
Conditions
Sudden Cardiac Death, Ventricular Arrythmias
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Aspirus Heart and Vascular Institute-Research and Education
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Wausau, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

NCT01843127
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Exenatide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 16, 2026, 11:03 PM EDT
Terminated Phase 2 Interventional Results available

Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents

NCT02147834
View directory record Official record
Conditions
Angina
Interventions
Ranolazine, Sugar pill
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 16, 2026, 11:03 PM EDT
Not listed Phase 4 Interventional

Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)

NCT03044964
View directory record Official record
Conditions
Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Amit Malhotra, MD
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Southaven, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 3 Interventional

Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes

NCT00099788
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
6,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 1 Interventional

A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension

NCT01757808
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 72 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 16, 2026, 11:03 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

NCT01555164
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
60
States / cities
Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Sep 16, 2026, 11:03 PM EDT